A 15-year-old tribal girl from Khammam district has undergone life-saving surgery after being diagnosed with a rare tumor ...

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Hematological Tumor.

The single-cell analysis revealed a diverse range of cell types within the tumor microenvironment (TME), including tumor cells, immune cells, and fibroblasts, with varying proportions across cases.

Clinical Features. Basal cell carcinoma (BCC) is the most common malignant eyelid tumor, accounting for 85% of all such tumors. [1] The tumor usually affects adults but may also occur in younger ...

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Unspecified B-Cell Lymphomas. According to GlobalData, Phase I drugs for Unspecified B-Cell Lymphomas does not ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes ... Additionally, pharmacologic inhibition of T cell glycolysis under hypoxia ...

18, 2024 — Scientists have generated human stem cell models which contain notochord ... lifetime could have implications ... How Breast Cancer Cells Survive in Bone Marrow After Remission ...

Other cancer immunotherapies include vaccines and T cell infusions. By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both ...

Tumors are the result of abnormal cell growth. Usually, the cells in your body grow and divide to form new cells whenever your body needs them. When older cells die, they’re replaced by new ones.

These new mutations may give rise to new characteristics of the cancer, such as the ability to spread more freely. Non-genetic cellular changes in cell behavior, called epigenetic changes, also occur.